Literature DB >> 437404

Erythromycin ethylsuccinate-induced cholestasis.

A L Viteri, J F Greene, W P Dyck.   

Abstract

A 52-year-old Caucasian female developed abdominal pain, fever, and jaundice after erythromycin ethylsuccinate administration. Similar symptoms followed the administration of the same drug 5 mo earlier. It is believed that this is the first published case of erythromycin ethylsuccinate-induced cholestasis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 437404

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

Review 1.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 2.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors:  Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2013-05-07       Impact factor: 3.534

3.  Demonstration of Epstein-Barr virus DNA in a previously healthy boy with fulminant hepatic failure.

Authors:  J Deutsch; H Wolf; H Becker; B Fuchs; U Goriup; H M Grubbauer; W Muntean; T Popow-Kraupp; D Stünzner
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

4.  Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.

Authors:  E B Keeffe; T C Reis; J E Berland
Journal:  Dig Dis Sci       Date:  1982-08       Impact factor: 3.199

5.  Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.

Authors:  J P Hosker; D P Jewell
Journal:  Postgrad Med J       Date:  1983-08       Impact factor: 2.401

6.  Therapeutic doses of erythromycin esteolate is not cholestatic in rats in vivo.

Authors:  I Fiebiger; M S Anwer; D Hegner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.